Literature DB >> 1475999

Atypical clinical manifestations of hepatitis A.

E R Schiff1.   

Abstract

Viral A hepatitis is a self-limited infection occurring predominantly among children usually as an anicteric often subclinical illness. Adults afflicted with this virus are more likely to develop icteric hepatitis. This is exemplified in developed countries when a common source outbreak occurs among non-immune adults. Fulminant hepatitis is uncommon in the USA and hepatitis A has never been documented to evolve into chronic hepatitis. However, prolonged cholestasis and relapsing hepatitis are well described. The usual features of cholestatic viral hepatitis A are pruritus, fever, diarrhoea, and weight loss. Serum bilirubin levels are > 10 mg/dl and the clinical course lasts at least 12 weeks. Cholestasis will spontaneously resolve, although corticosteroids will hasten the resolution but may predispose the patient to develop a relapse of the hepatitis. A biphasic or relapsing form of viral hepatitis A occurs in 6 to 10% of cases. The initial episode lasts 3 to 5 weeks and is followed by a period of remission characterized by normal liver chemistries lasting 4 to 5 weeks. Relapse may mimic the initial episode of the acute hepatitis. The full duration of the illness ranges from 16 to 40 weeks from the onset and immunoglobulin M antibody to hepatitis A virus persists throughout the clinical course. Hepatitis A virus has been recovered from stools during the relapse. Extrahepatic manifestations of hepatitis A include evanescent skin rash and transient arthralgias. Documented cases of arthritis and cutaneous vasculitis have been associated with cryoglobulinaemia and are rare.

Entities:  

Mesh:

Year:  1992        PMID: 1475999     DOI: 10.1016/0264-410x(92)90534-q

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  30 in total

1.  All patients with acute hepatitis must be observed until the acute liver injury resolves.

Authors:  D E Johnston
Journal:  West J Med       Date:  2000-01

2.  Diagnostic approach to patients with cholestatic jaundice.

Authors:  N Assy; G Jacob; G Spira; Y Edoute
Journal:  World J Gastroenterol       Date:  1999-06       Impact factor: 5.742

3.  Immunoglobulin A (IgA) is a natural ligand of hepatitis A virus cellular receptor 1 (HAVCR1), and the association of IgA with HAVCR1 enhances virus-receptor interactions.

Authors:  Cecilia Tami; Erica Silberstein; Mohanraj Manangeeswaran; Gordon J Freeman; Sarah E Umetsu; Rosemarie H DeKruyff; Dale T Umetsu; Gerardo G Kaplan
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

4.  Prolonged acute hepatitis A mimicking autoimmune hepatitis.

Authors:  Rintaro Mikata; Osamu Yokosuka; Fumio Imazeki; Kenichi Fukai; Tatsuo Kanda; Hiromitsu Saisho
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

Review 5.  [Hepatitis associated cryoglobulinemia].

Authors:  S Pischke; M Cornberg; M P Manns
Journal:  Internist (Berl)       Date:  2008-03       Impact factor: 0.743

Review 6.  Adaptive Immune Responses in Hepatitis A Virus and Hepatitis E Virus Infections.

Authors:  Christopher M Walker
Journal:  Cold Spring Harb Perspect Med       Date:  2019-09-03       Impact factor: 6.915

7.  Autoimmune liver disease following acute hepatitis A infection.

Authors:  Hannah Yeend-Curd-Trimble; Kate Kelly; Indrajit Ghosh; Douglas MacDonald
Journal:  BMJ Case Rep       Date:  2019-05-30

8.  Cost effectiveness of hepatitis A prevention in France.

Authors:  C A Severo; F Fagnani; A Lafuma
Journal:  Pharmacoeconomics       Date:  1995-07       Impact factor: 4.981

9.  Association of henoch-schoenlein purpura with hepatitis a.

Authors:  Mohammad-Saeed Sasan; Mostafa Almasi Doghaee
Journal:  Iran J Pediatr       Date:  2012-12       Impact factor: 0.364

10.  Valuation of symptomatic hepatitis a in adults: estimates based on time trade-off and willingness-to-pay measurement.

Authors:  R Jake Jacobs; Ronald J Moleski; Allen S Meyerhoff
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.